The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
 
Catherine Labbe
No Relationships to Disclose
 
Grzegorz Korpanty
No Relationships to Disclose
 
Pascale Tomasini
No Relationships to Disclose
 
Mark Doherty
No Relationships to Disclose
 
Celine Mascaux
No Relationships to Disclose
 
Kevin Jao
No Relationships to Disclose
 
Bethany Pitcher
No Relationships to Disclose
 
Melania Pintilie
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
 
Ronald Feld
No Relationships to Disclose
 
Geoffrey Liu
No Relationships to Disclose
 
Penelope Ann Bradbury
No Relationships to Disclose
 
Suzanne Kamel-Reid
No Relationships to Disclose
 
Ming Sound Tsao
Honoraria - Boehringer Ingelheim; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; Novartis; Pfizer; Roche; Syntha Pharmaceutical
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Prognostic gene signature for early stage non-small cell lung cancer
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck/Schering Plough; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Recombio; Synta
Research Funding - Boehringer Ingelheim (Inst)